MoonLake Immunotherapeutics (MLTX) announced the week 16 results of the Phase 3 VELA-1 and VELA-2 trials of its registrational global program in patients with moderate-to-severe hidradenitis suppurativa. Both VELA-1 and VELA-2 achieved statistical significance for all key secondary endpoints. This includes other lesion count based endpoints. It also includes relevant PROs in HS. Around 30% of patients experienced a marked reduction of pain, as measured by an at least 3-point improvement in the worst pain NRS, in both VELA-1 and VELA-2. Sonelokimab showed a significant improvement of HiSQOL score at week 16. which was consistent between VELA-1 and VELA-2. Almost 60% of patients achieved a meaningful improvement of DLQI, an approximately 20 percentage-point benefit over placebo.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- Short Report: Viking Therapeutics short interest at 5-year high after VK273 data
- Buy Rating for MoonLake Immunotherapeutics: Anticipated Success of Sonelokimab in Phase 3 VELA Trial
- MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 VELA Program and Robust Financial Position
- MoonLake Immunotherapeutics Reports Q2 2025 Financials
- MoonLake Immunotherapeutics: Buy Rating Driven by Promising SLK Phase 3 Data and Strong Financial Position